Transnasal anticonvulsive pharmaceutical composition
Disclosed herein is a transnasal anticonvulsive pharmaceutical composition comprising diazepam as an active ingredient, water, a fatty acid ester, diethylene glycol monoethyl ether, ethanol and sodium glycocholate, wherein the weight of the fatty acid ester is at least 2-fold higher than that of water and is at least 2-fold higher than that of ethanol. The anticonvulsive pharmaceutical composition for transmucosal delivery of diazepam according to the present invention includes a minimized content of water and ethanol, a fatty acid ester as a main ingredient and no use of a polar solvent, e.g. glycol, and, exhibits improved diazepam solubility and transmucosal permeability due to using a small amount of water and ethanol. The present invention also includes treatment of convulsions by transnasally administering to a patient in need thereof a therapeutically effective amount of the disclosed compositions.
1. A transnasal anticonvulsive pharmaceutical composition comprising from about 4 to 6% by weight of diazepam as an active ingredient, from about 8 to 12% by weight of water, a fatty acid ester, from about 30 to 45% by weight of diethylene glycol monoethyl ether, from about 12 to 17% by weight of ethanol and from about 0.5 to 1.2% by weight of sodium glycocholate, wherein the weight of the fatty acid ester is at least 2-fold higher than that of water and is at least 2-fold higher than that of ethanol, the fatty acid ester is contained in an amount of from about 38 to 42% by weight, based on the total weight of the composition, and is a mixture of caprylocaproyl macrogol-8-glycerides and ethyl laurate in a weight ratio of from 4.5:3.5 to 5.5:2.5.
2. A method for treating a convulsion, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 to a patient suffering from the convulsion.